Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.